Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Biofrontera Inc. (BFRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.9500-0.0900 (-1.79%)
At close: 04:00PM EST
4.9500 0.00 (0.00%)
After hours: 07:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.1300
Open5.1400
Bid4.8900 x 2200
Ask4.9500 x 1000
Day's Range4.9100 - 6.5799
52 Week Range2.2500 - 14.6300
Volume8,874,877
Avg. Volume19,957,316
Market Cap74.527M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.9240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.50
  • GlobeNewswire

    Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

    WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter and full year ended December 31, 2021. Revenue for the fourth quarter of 2021 is anticipated to be in the range of approximately $9.1 million to $9.2 million, an increase of approximately 7% over the same quarter last year. Revenue for the full

  • GlobeNewswire

    Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January

    WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that it plans to participate in the following two dermatology conferences in January: 2022 Winter Clinical Dermatology Conference at the Grand Hyatt in Kauai, January 14-19, 2022Maui Derm for Dermatologists 2022 at the Grand Wailea, January 24-28, 2022 At each conference, clinical data for B

  • GlobeNewswire

    Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises

    WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownership of Biofrontera AG was diluted below 50%. Biofrontera AG’s shareholding in Biofrontera Inc. of 8,000,000 shares is unchanged, but now represents approximately 47% of the currently outstanding shares. As a result, Biofrontera Inc. is no longer

Advertisement
Advertisement